Human papilloma virus (HPV) is responsible for 72% of oropharyngeal,70% of cervical, 90% of anal and 71% of vulvar, vaginal, or penile cancers, causing significant morbidity and mortality worldwide [1,2].CUE-101, a novel fusion protein designed to activate tumor antigen-specific T cells to treat HPV16-driven cancers, is comprised of a human leukocyte antigen (HLA) complex, HLA-A*0201, a peptide epitope derived from the human HPV16 E7 protein (amino acid residues 11-20), a reduced affinity human interleukin-2 (IL-2) variant, and an effector attenuated human immunoglobulin G (IgG1) Fc domain. The gene discussed is IL2; the disease is cancer.